---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008994"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:53:32.819957+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ZyVersa raises $1M via convertible notes and warrants for working capital

## Summary
- Issued $1M aggregate principal 10% convertible promissory notes, maturing in 12 months, with a $0.02 floor price on conversion.
- Notes convertible at 80% of the lowest daily VWAP during the 10 trading days prior to conversion notice.
- Series A-4 warrants exercisable six months post-issuance, expiring in 5 years; exercise price linked to qualified offering or VWAP.
- Proceeds to be used for working capital; obligations guaranteed by subsidiary ZyVersa Therapeutics Operating, Inc.
- Securities sold to accredited investors in a private placement under Section 4(a)(2) and Regulation D.

## SEC filing metadata
- accession: 0001493152-26-008994
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000149315226008994/0001493152-26-008994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000149315226008994/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008994
- JSON: https://secwatch.observer/filing/0001493152-26-008994.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008994.txt

## Key facts
- Material Agreements
  ZyVersa Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $1 million (effective 2026-02-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: $1 million
  - Effective: 2026-02-27
  source text: On February 27, 2026, ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company issued and sold to the Purchasers convertible promissory notes in an aggregate principal amount of $1 million (the “Notes”) and Series A-4 Common Stock Purchase Warrants (the “Warrants”) to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1859007/000149315226008994/0001493152-26-008994-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.